[1]
|
Edmond MB, Wallance SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals:a three-year analysis[J]. Clin Infect Dis, 1999, 29(2):234. |
[2]
|
Li L, Ding H, Wang B, et al. Synthesis and evaluation of novel azoles as potent antifungal agents[J]. Bioorg Med Chem Lett, 2014, 24(1):192-194. |
[3]
|
Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stemcell transplant recipients[J]. Clin Infect Dis, 2002, 7:909-917. |
[4]
|
Ramirez E, Garcia-Rodriguez J, Borobia AM, et al. Use of antifungal agents in pediatric and adult high-risk areas[J]. Eur J Clin Microbiol Infect Dis, 2012, 3:337-347. |
[5]
|
Desai VC, Cavanaugh TM, Kelton CM, et al. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs:1991-2009[J]. Clin Ther, 2012, 10:2118-2131. |
[6]
|
Jiang Z, Wang Y, Wang W, et al. Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement[J]. Eur J Med Chem, 2013, 64:16-22. |
[7]
|
Wang S, Jin G, Wang W, et al. Synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxpropylamino side chains[J]. Eur J Med Chem, 2012, 53(4):292-299. |
[8]
|
Richardson K. Antifungal 1,3-bis-triazolyl-2-propanol derivative:4404216[P]. USA, 1983-09-13. |
[9]
|
Zou Y, Yu S, Li R, et al. Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates[J]. Eur J Med Chem, 2014, 74:366-374. |
[10]
|
National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts approved standard[S]. Document M27-A2, Wayne, PA, 2002. |